Transperineal Cryotherapy for Unresectable Muscle Invasive Bladder Cancer: Preliminary Experience with 7 Male Patients

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2017 Sep 11

PMID 28888228

Citations 3

Authors

Qing Zhang

Shiwei Zhang

Shun Zhang

Wei Wang

Xiaozhi Zhao

Yongming Deng

Huibo Lian

Hongqian Guo

Affiliations

Soon will be listed here.

Abstract

Background: Radical cystectomy (RC) with pelvic lymph node dissection (PLND) and urinary diversion (UD) is considered the standard treatment for muscle invasive bladder cancer (MIBC). In a part of patients, RC procedure is aborted due to unresectable disease, other followed treatment like systemic chemotherapy, radiotherapy or cryotherapy may be a better option. The aim of present study was to report the preliminary results of transperineal cryotherapy for unresectable muscle invasive bladder cancer.

Methods: From January 2011 to August 2013, 7 male patients with pT4b unresectable bladder cancer underwent bilateral ureterocutaneostomy. Two performed a pelvic lymph node dissection (PLND). Then primary transperineal cryosurgery for preserved bladder at the guidance of transrectal ultrasound (TRUS) was performed. All patients underwent a dual freeze-thaw cycle using third-generation cryotechnology with ultrathin 17-gauge cryoneedles. Computer tomography (CT) and/or magnetic resonance image (MRI)were performed at 3 month intervals after cryosurgery to determine whether progression or recurrence occurred.

Results: All cryosurgery was performed successfully, mean operation time was 76.43 ± 25.12 min (range 50-120 min), mean blood loss was 19.29 ± 15.92 ml (range 5-50 ml). Mean hospital stay was 3.86 ± 1.68 day (range 2-7 days). No operative related deaths occurred. Four patients dead due to the metastasis disease at the follow up time of 8, 15, 18 and 37 months, respectively. Six patients received postoperative therapy, of whom 5 patients were treated with combined chemoradiation, and the other one received chemotherapy alone. The progression free survival (PFS) of the 7 patients was 22.00 ± 14.61 months (range 3-40 months). The one, two and three year overall survival (OS) was 85.7%, 57.1% and 42.9%, respectively.

Conclusion: Our results suggest that cryosurgery combination with chemoradiotherapy provide a safe and effective alternative method for unresectable pT4b bladder cancer. Longer follow-up is necessary to determine the sustained efficacy.

Citing Articles

Application of cryoablation in animal models of bladder and muscle-invasive bladder cancer: a narrative review of current status and future perspectives.

Wang Y, Li X Quant Imaging Med Surg. 2024; 14(12):9653-9666.

PMID: 39698593 PMC: 11652053. DOI: 10.21037/qims-24-1174.

Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Kwak K, Yu B, Lewandowski R, Kim D Theranostics. 2022; 12(5):2175-2204.

PMID: 35265206 PMC: 8899563. DOI: 10.7150/thno.67530.

Investigation of Bladder Cancer Cell Response to Cryoablation and Adjunctive Cisplatin Based Cryo/Chemotherapy.

Santucci K, Baust J, Snyder K, Van Buskirk R, Katz A, Corcoran A Clin Res (Milpitas). 2022; 6(1).

PMID: 35128225 PMC: 8813088. DOI: 10.16966/2469-6714.154.

References

Dunst J, Rodel C, Zietman A, Schrott K, Sauer R, Shipley W . Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001; 20(1):24-32. DOI: 10.1002/ssu.1013. View

Glenn J, Alyea E . Ureterocutaneous anastomosis. I. Experimental use of a surgical splint to prevent stricture. J Urol. 1960; 83:602-5. DOI: 10.1016/S0022-5347(17)65764-1. View

Liang Z, Fei Y, Lizhi N, Jianying Z, Zhikai Z, Jibing C . Percutaneous cryotherapy for metastatic bladder cancer: experience with 23 patients. Cryobiology. 2013; 68(1):79-83. DOI: 10.1016/j.cryobiol.2013.12.004. View

Marcus D, Canter D, Jani A, Dobbs R, Schuster D, Carthon B . Salvage therapy for locally recurrent prostate cancer after radiation. Can J Urol. 2012; 19(6):6534-41. View

Herr H, Donat S . Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol. 2000; 165(1):62-4; discussion 64. DOI: 10.1097/00005392-200101000-00015. View

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

Logan C, Brown M, Hayne D . Intravesical therapies for bladder cancer - indications and limitations. BJU Int. 2012; 110 Suppl 4:12-21. DOI: 10.1111/j.1464-410X.2012.11619.x. View

Schiffman M, Moshfegh A, Talenfeld A, Del Pizzo J . Laparoscopic renal cryoablation. Semin Intervent Radiol. 2014; 31(1):64-9. PMC: 3930655. DOI: 10.1055/s-0033-1363844. View

Goldberg S, Grassi C, Cardella J, Charboneau J, Dodd 3rd G, Dupuy D . Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009; 20(7 Suppl):S377-90. DOI: 10.1016/j.jvir.2009.04.011. View

10.

Sverrisson E, Stephen Jones J, Pow-Sang J . [Cryosurgery for prostate cancer: a comprehensive review]. Arch Esp Urol. 2013; 66(6):546-56. View

11.

McDonald J, Taylor C, HECKEL N . Rapid freezing of the bladder: an experimental and clinical study. J Urol. 1950; 64(2):326-37. DOI: 10.1016/S0022-5347(17)68637-3. View

12.

Yafi F, Duclos M, Correa J, Tanguay S, Aprikian A, Cury F . Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. Urol Oncol. 2009; 29(3):309-13. DOI: 10.1016/j.urolonc.2009.04.017. View

13.

Hartman J, Bhojwani N, Corn D, Cooney M, Haaga J, Ponsky L . Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experience. J Vasc Interv Radiol. 2014; 25(5):776-9. PMC: 3995864. DOI: 10.1016/j.jvir.2014.01.027. View

14.

Lian H, Guo H, Gan W, Li X, Yan X, Wang W . Cryosurgery as primary treatment for localized prostate cancer. Int Urol Nephrol. 2011; 43(4):1089-94. DOI: 10.1007/s11255-011-9952-7. View

15.

Nagele U, Anastasiadis A, Merseburger A, Corvin S, Hennenlotter J, Adam M . The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol. 2007; 25(4):401-5. DOI: 10.1007/s00345-007-0172-9. View

16.

Loehrer Sr P, Einhorn L, Elson P, Crawford E, Kuebler P, Tannock I . A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10(7):1066-73. DOI: 10.1200/JCO.1992.10.7.1066. View

17.

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

18.

Custodio S, Joaquim A, Peixoto V, Macedo J, Faria A, Macias E . Metastatic renal cell carcinoma: the importance of immunohistochemistry in differential diagnosis. Case Rep Oncol. 2012; 5(1):30-4. PMC: 3290036. DOI: 10.1159/000335683. View

19.

Chen B, Zeng Z, Wang G, Zhang L, Lin Z, Sun L . Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer. 2011; 11:297. PMC: 3155495. DOI: 10.1186/1471-2407-11-297. View

20.

Sverrisson E, Nguyen H, Kim T, Pow-Sang J . Primary cryosurgery for clinically localized prostate cancer--do perioperative tumor characteristics correlate with post-treatment biopsy results?. Urology. 2013; 83(2):376-8. DOI: 10.1016/j.urology.2013.10.018. View